Guided Therapeutics, Inc.
4955 Avalon Ridge Parkway
Suite 300
Norcross
Georgia
30071
United States
Tel: 770-242-8723
Fax: 770-242-8639
Website: http://www.guidedtherapeutics.com/
Email: info@guidedtherapeutics.com
203 articles about Guided Therapeutics, Inc.
-
Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval
11/20/2023
Guided Therapeutics, Inc. (OTCQB: GTHP) announced today the completion of the clinical trial for marketing and sales approval of the Company’s LuViva Advanced Cervical Scan by the Chinese National Medical Products Administration (NMPA).
-
Guided Therapeutics Provides Update on Start of Clinical Trial for US FDA Approval
5/1/2023
Guided Therapeutics, Inc. or the “Company” (OTCQB: GTHP), the maker of LuViva, a rapid and painless cervical cancer detection system based on the Company’s patented biophotonic technology, provided an update regarding the start of its pivotal clinical trial.
-
Guided Therapeutics Announces New Agreement and Purchase Orders from Shandong Yaohua Medical Instrument Corporation
3/15/2023
Guided Therapeutics, Inc. announced that it had signed a new agreement with the Company’s Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation.
-
Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval
12/21/2022
Guided Therapeutics, Inc. or the “Company” (OTCQB: GTHP), the maker of LuViva, a rapid and painless cervical cancer detection system based on the Company’s patented biophotonic technology, announced today it had executed a Clinical Trial Agreement with a prestigious academic medical institution.
-
Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan
11/9/2022
Guided Therapeutics, Inc. (OTCQB: GTHP) announced today that the clinical trial for Chinese regulatory is back on track after experiencing delays due to Covid-19 lockdowns and is expected to be completed and filed with the Chinese National Medical Products Administration (NMPA) during the first half of 2023.
-
Guided Therapeutics Closes $3.3 Million Bridge Financing
9/7/2022
Guided Therapeutics, Inc. or the “Company”, the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that it had raised approximately $3.3 million through the sale of 6.6 million shares of the Company’s common stock at 50 cents each.
-
Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan
7/20/2022
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced that it has obtained Institutional Review Board (IRB) approval to initiate its clinical trial aimed at obtaining FDA approval for the Company’s flagship product, the LuViva Advanced Cervical Scan.
-
Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740
3/31/2022
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that testing of 150 patients has been completed in the ongoing clinical trial for Chinese National Medical Products Administration (NMPA) approval.
-
Guided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China
11/17/2021
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that enrollment and testing of patients has begun at the Department of Obstetrics & Gynecology Hospital of Fudan University located in Shanghai.
-
Guided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 Payment
10/5/2021
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that its Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI), had received ethics board approval and placed LuViva devices at two of the three participating hospitals for clinical trials aimed at achieving Chinese FDA approval.
-
Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China
8/19/2021
Guided Therapeutics, Inc. announced today it had passed the regulatory compliance review at the Department of Obstetrics & Gynecology Hospital of Fudan University located in Shanghai.
-
Guided Therapeutics Receives News from Chinese State Food and Drug Administration that LuViva Meets Product Technical Requirements
7/20/2021
Guided Therapeutics, Inc. announced today its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation (SMI), has received notice from the Jinan Medical Device Quality Supervision and Testing Center of the State Food and Drug Administration that LuViva has passed safety and electromagnetic compliance requirements necessary to be used in clinical trials.
-
Guided Therapeutics Replaces Convertible Note Facility and Significantly Reduces Dilution
6/3/2021
Guided Therapeutics, Inc. or the “Company”, the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that it has raised an additional US $1.13 million under the terms of a 3-year convertible debenture.
-
Guided Therapeutics Closes $2.114 Million Series F Preferred Stock Financing
3/31/2021
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it had closed its Series F Preferred Stock Financing on March 26, 2021
-
Guided Therapeutics Raises US $1.1 Million in New Preferred Stock Offering
2/16/2021
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has thus far raised a total of US $1.1 million under the terms of a Series F Preferred Stock Offering.
-
Guided Therapeutics Makes Final Payment to GPB Capital Holdings for Secured Notes
1/13/2021
Guided Therapeutics, Inc., the maker of the LuViva Advanced Cervical Scan, announced that it had made the final payment of $750,000 to GPB Capital Holdings, LLC under a cash and equity exchange agreement signed on January 16, 2020.
-
Guided Therapeutics Receives New Half Million Dollar Purchase Order from China
1/5/2021
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva® Advanced Cervical Scan, based on its patented biophotonic technology, announced today that it had received a new purchase order in the amount of $530,695 from its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation (SMI). The new purchase order, which was issued by SMI based on its progress with
-
Guided Therapeutics Announces Sales and Training Center in Budapest
12/21/2020
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced the opening of a new LuViva Reference and Training Center (“Center of Excellence”) in Budapest, Hungary to support sales and training in Europe. The
-
After Meeting with FDA, Guided Therapeutics to Start Study in Support of its Application for FDA Approval
10/21/2020
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, announced today the successful outcome of its October 14, 2020 meeting with FDA. The purpose of the meeting was to finalize the protocol (procedure) for its n
-
Guided Therapeutics Ships LuViva Devices and Disposables for Chinese FDA Pivotal Clinical Trial
9/14/2020
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that it had shipped four LuViva Advanced Cervical Scan systems and associated disposables to its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation. Shandon